Indian CRAMs Benefit From Global Slowdown With Increase Business
This article was originally published in PharmAsia News
The contract research and manufacturing industry in India not only is weathering the global economic crisis, its business is increasing. Some foreign drug makers have stepped up their outsourcing to India to take advantage of reduced costs that can save some multinational companies as much as 40 percent. Analysts expect the CRAM business in India to reach the $3 billion mark a year from now, equal to a growth rate of 42 percent. The increase in CRAM business in India is the opposite of the experiences of other outsourcing businesses in the country. (Click here for more
You may also be interested in...
US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.
Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.